In this podcast, expert clinicians will discuss current and future approaches for the management of patients with uveitis.
In this podcast, expert clinicians will discuss the utilization of surgery in the management of patients with retinal diseases.
In this podcast, expert clinicians will discuss the utilization of imaging in patients with retinal diseases.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with retinal vein occlusion.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with neovascular age-related macular degeneration, dry age-related macular degeneration, and geographic atrophy.
In this podcast, expert clinicians will discuss current and future approaches for the management of patients with diabetic eye disease.
In this podcast, expert clinicians will discuss best practices for reducing ocular toxicities in myeloma patients through the multidisciplinary team.
In this podcast, expert clinicians will discuss strategies to mitigate and manage ocular toxicities related to multiple myeloma therapy.
In this podcast, expert clinicians will discuss the frequency and identification of ocular toxicities of patients on myeloma therapy.
In this podcast, expert clinicians will discuss the mechanisms behind ocular toxicities that have been associated with antibody drug conjugates used for cancer treatment.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Arshad Khanani discuss the efficacy and safety of therapies targeting Ang-2 in nAMD.
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Judy Kim discuss the Tie2 pathway and its role in the pathophysiology of retinal vascular diseases.
In this podcast, expert clinicians will discuss best practices regarding the use of Port Delivery System with ranibizumab.
In this podcast, expert clinicians will discuss achieving vascular stability through inhibition of Ang-2. To obtain CME credit, go here: https://tinyurl.com/y58538ef
In this podcast, expert clinicians will discuss emerging gene therapies for AMD and DME. To obtain CME credit, go here: https://tinyurl.com/yusxpn44
In this podcast, expert clinicians will discuss emerging delivery system devices in neovascular retinal disease. To obtain CME credit, please go here: https://tinyurl.com/thma9fwp
In this podcast, expert clinicians will discuss diagnosing and managing a challenging case of neuromyelitis optica spectrum disorder (NMOSD).
In this podcast, expert clinicians will discuss clinical trial data of biologics used in neuromyelitis optica spectrum disorder (NMOSD).
In this podcast, expert clinicians will discuss the mechanisms of action of biologics used in neuromyelitis optica spectrum disorder (NMOSD).